Antoinette Wozniak, MD, FACP, FASCO, highlights the importance of monitoring patients with lung cancer for toxicities and significant advances on the horizon that are expected to further expand the lung cancer armamentarium.
The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.
Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.
Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.
Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of hematologic oncology.